К ВОПРОСУ ОБ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ НА ФОНЕ ОЖИРЕНИЯ В ПЕРИОД ПАНДЕМИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19

Статья в Elpub

Валеология: Здоровье, Болезнь, Выздоровление. 2021; : 5-12

К ВОПРОСУ ОБ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ НА ФОНЕ ОЖИРЕНИЯ В ПЕРИОД ПАНДЕМИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19

Аннотация

В обзорной статье подробно освещены данные из литературы о влиянии артериальной гипертензии и абдоминального ожирения на течение коронавирусной инфекции COVID-19. Во всем мире сегодня распространенность артериальной гипертензии (АГ) среди взрослого населения составляет 30-45 %, а у лиц старше 60 лет – более 60 %, что обусловлено не только старением населения, но и такими поведенческими факторами риска, как избыточный вес и ожирение. Известно, что АГ страдают в два раза чаще люди с абдоминальным ожирением. Особую опасность для больных с АГ и избыточной массой тела представляет коронавирусная инфекция COVID-19, особенно в случаях тяжелого течения, которая способствует возникновению сосудистых тромбозов и декомпенсации имеющихся хронических заболеваний. В связи с этим в обзоре литературы подчеркивается необходимость изучения клинико-функциональных характеристик АГ у лиц с абдоминальным ожирением, перенесших коронаровирусную инфекцию.

Список литературы

1. Akoumianakis I., Filippatos T. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity // Obes Rev. 2020. -Sep; 21 (9): e13077. doi:10.1111/obr.13077. Epub 2020 Jun 22.

2. Arroyo-Johnson C., Mincey K. D. Obesity Epidemiology Worldwide. //Gastroenterol Clin. North. Am. 2016. - Dec; 45 (4): 571-579. doi: 10.1016/j.gtc.2016.07.012.

3. Barber T. M., Kyrou I., Randeva H. S., Weickert M. O. Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction // Int J Mol Sci. 2021 - . Jan 7; 22 (2): 546. doi: 10.3390/ijms22020546.

4. Bhatraju P. K., Ghassemieh B. J., Nichols M., e. a. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series // N Engl J Med.2020. - May 21; 382 (21): 2012. - 2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.

5. Bornstein S. R., Rubino F., Khunti K., e. a. Practical recommendations for the management of diabetes in patients with COVID-19. //Lancet Diabetes Endocrinol. 2020 Jun; 8 (6): 546-550. doi: 10.1016/S2213-8587(20)30152-2. Epub 2020 Apr 23.

6. Бойцов С. А. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования эссе / С. А. Бойцов [и др.] // КВТиП. – 2014. – № 4. – C. 4-14.

7. ВОЗ. Ожирение и избыточный вес. – Апрель 2020 //Информационный бюллетень.

8. Cleven L., Krell-Roesch J., Nigg C. R., Woll A. The association between physical activity with incident obesity, coronary heart disease, diabetes and hypertension in adults: a systematic review of longitudinal studies published after 2012 // BMC Public Health. 2020 May 19; 20 (1): 726. doi: 10.1186/s12889-020-08715-4.

9. Джиджихия К. М. ЛЕПТИН И АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ ПРИ МЕТАБОЛИЧЕСКОМ СИНДРОМЕ К. М. Джиджихия [и др.] // Успехи современного естествознания. – 2013. – № 7. – С. 159-159А.

10. Ettehad, D., Emdin C. A., Kiran A., e. a. (2016) Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis // Lancet, 387, 957-967.

11. Ерина А. М. Эпидемиология артериальной гипертензии в Российской Федерации – важность выбора критериев диагностики / А. М. Ерина [и др.] // Кардиология. – 2019. Т. 59 (6). – С. 5-11.

12. Finer N., Garnett S. P., Bruun J. M. COVID-19 and obesity. // Clin Obes. 2020 Jun; 10 (3): e12365. doi: 10.1111/cob.12365. Epub 2020 Apr 27.

13. Földi M., Farkas N., Kiss S., е. а. KETLAK Study Group. Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis // Obes Rev. 2020 Oct; 21 (10): e13095. doi:10.1111/obr.13095. Epub 2020 Jul 19.

14. Garg S., Kim L., Whitaker M., е. а. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020 // MMWR Morb Mortal Wkly Rep. 2020 Apr 17; 69 (15): 458-464. doi: 10.15585/mmwr.mm6915e3.

15. Global B. M. I. Mortality Collaboration, Di Angelantonio E., Bhupathiraju Sh. N., Wormser D., е. а. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents // Lancet. 2016 Aug 20; 388 (10046): 776-86. doi: 10.1016/S0140-6736(16)30175-1. Epub 2016 Jul 13.

16. Hussain A., Mahawar K., Xia Z., e. a. Obesity and mortality of COVID-19. Meta-analysis // Obes Res Clin Pract. 2020 Jul-Aug;14 (4): 295-300. doi: 10.1016/j.orcp.2020.07.002. Epub 2020 Jul 9. Retraction in: Obes Res Clin Pract. 2021 Jan-Feb; 15 (1): 100.

17. Ибрагимова Х. И. Половые особенности регуляции артериального давления и лечения артериальной гипертензии / Х. И. Ибрагимова, С. Н. Маммаев, Д. А. Омарова // Артериальная Гипертензия. – 2018. – № 3. – С. 303-308.

18. Jayedi A., Soltani S., Zargar M. S., e. a. Central fatness and risk of all-cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies // BMJ. 2020 Sep 23; 370: m3324. doi: 10.1136/bmj.m3324.

19. Joffres M., Falaschetti E., Gillespie C. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study // BMJ Open 2013; 3: e003423. doi: 10.1136/bmjopen-2013–003423.

20. Kim J. S., Lee J. Y., Yang J. W., е. а. Immunopathogenesis and treatment of cytokine storm in COVID-19 // Theranostics. 2021 Jan 1; 11 (1): 316-329. doi: 10.7150/thno.49713.

21. Konukoglu D., Uzun H. Endothelial Dysfunction and Hypertension // Adv Exp Med Biol. 2017; 956: 511-540. doi: 10.1007/5584_2016_90.

22. Kotsis V., Jordan J., Micic D., е. а. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment // J Hypertens. 2018 Jul; 36 (7): 1427-1440. doi: 10.1097/HJH.0000000000001730.

23. Lee B. J., Yim M. H. Comparison of anthropometric and body composition indices in the identification of metabolic risk factors. // Sci Rep. 2021 May 11; 11 (1): 9931. doi: 10.1038/s41598-021-89422-x.

24. Luo D., Cheng Y., Zhang H., е. а. Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis // BMJ. 2020 Sep 9; 370: m3222. doi: 10.1136/bmj.m3222.

25. Mayer S. B., Graybill S., Raffa S. D., e. a. Synopsis of the 2020 U. S. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity // Mil Med. 2021 Apr 27: usab114. doi: 10.1093/milmed/usab114. Epub ahead of print.

26. Mills K. T., Stefanescu A., He J. The global epidemiology of hypertension // Nat Rev Nephrol. 2020 Apr; 16 (4): 223-237. doi: 10.1038/s41581-019-0244-2. Epub 2020 Feb 5.

27. Muscogiuri G., Pugliese G., Barrea L., e. a. Commentary: Obesity: The "Achilles heel" for COVID-19? // Metabolism. 2020 Jul; 108: 154251. doi: 10.1016/j.metabol.2020.154251. Epub 2020 Apr 27.

28. Ononamadu C. J., Ezekwesili C. N., Onyeukwu O. F., е. а. Comparative analysis of anthropometric indices of obesity as correlates and potential predictors of risk for hypertension and prehypertension in a population in Nigeria // Cardiovasc J Afr. 2017 Mar / Apr 23; 28 (2): 92-99. doi: 10.5830/CVJA-2016-061. Epub 2016 Jul 13.

29. Осипова А. А. Роль лептина в регуляции энергетического обмена и функционировании организмов живой природы / А. А. Осипова //Окружающая среда и энерговедение. – 2019. – № 2. – С. 55-82.

30. Pedralli M. L., Marschner R. A., Kollet D. P., е. а. Different exercise training modalities produce similar endothelial function improvements in individuals with prehypertension or hypertension: a randomized clinical trial Exercise, endothelium and blood pressure. //Sci Rep. 2020 May 6; 10 (1): 7628. doi: 10.1038/s41598-020-64365-x.

31. Pellicori P., Doolub G., Wong C. M., е. а. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies // Cochrane Database Syst Rev. 2021 Mar 11; 3 (3): CD013879. doi: 10.1002/14651858.CD013879.

32. Petrilli C. M., Jones S. A., Yang J., e. a. Factors associated with hospitalization and critical illness among 4,103 patients with COVID‐19 disease in New York // med Rxiv. 2020. 04. 08. 20057794 10.1101/2020.04.08.20057794. Posted April 11, 2020. Accessed April 19, 2020.

33. Puig-Domingo M., Marazuela M., Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology // Endocrine. 2020 Apr; 68 (1): 2-5. doi: 10.1007/s12020-020-02294-5.

34. Rahman M. M., Gilmour S. Prevention and control of hypertension in different countries // JAMA. 2014 Jan 22-29; 311 (4): 418-9. doi: 10.1001/jama.2013.285324.

35. Rapsomaniki E., Timmis A., George J., е. а. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people // Lancet. 2014 May 31; 383 (9932): 1899-911. doi: 10.1016/S0140-6736(14)60685-1.

36. Sattar N., McInnes I. B., McMurray J. J. V. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020 Jul 7; 142 (1): 4-6. doi: 10.1161/CIRCULATIONAHA.120.047659. Epub 2020 Apr 22.

37. Schmidt B. M., Durao S., Toews I., e. а. Screening strategies for hypertension // Cochrane Database Syst Rev. 2020 May 7; 5 (5): CD013212. doi: 10.1002/14651858.CD013212.pub2.

38. Scioli M. G., Storti G., D'Amico F., e. а. Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets // J Clin Med. 2020 Jun 25; 9 (6): 1995. doi: 10.3390/jcm9061995.

39. Shalnova S. A., Conradi A. O., Karpov Yu. A., e. a. Cardiovascular mortality in 12 Russian federation regions – participants of the “Cardiovascular disease epidemiology in Russian regions” study // Russ J Cardiol 2012; 5 (97): 6–11. Russian (Шальнова С. А. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании “Эпидемиология сердечно-сосудистых заболеваний в различных регионах России” С. А. Шальнова [и др.] // Российский кардиологический журнал. – 2012. – 5 (97): 6–11).

40. Simonnet A., Chetboun M., Poissy J., е. а. LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation // Obesity (Silver Spring). 2020 Jul; 28 (7): 1195-1199. doi:10.1002/oby.22831. Epub 2020 Jun 10.

41. Vecchié A., Dallegri F., Carbone F., е. а. Obesity phenotypes and their paradoxical association with cardiovascular diseases. // Eur J Intern Med. 2018 Feb; 48: 6-17. doi: 10.1016/j.ejim.2017.10.020.

42. Williams B., Mancia G., Spiering W., е. а. ESC Scientific Document Group. 2018 ESC / ESH Guidelines for the management of arterial hypertension // Eur Heart J. 2018 Sep 1; 39 (33): 3021-3104. doi: 10.1093/eurheartj/ehy339.

43. Wu Z., McGoogan J. M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention // JAMA. 2020 Apr 7; 323 (13): 1239-1242. doi: 10.1001/jama.2020.2648.

44. Xia J. Y., Lloyd-Jones D. M., Khan S. S. Association of body mass index with mortality in cardiovascular disease: New insights into the obesity paradox from multiple perspectives. // Trends Cardiovasc Med. 2019 May; 29 (4): 220-225. doi: 10.1016/j.tcm.2018.08.006. Epub 2018 Aug 22.

45. Yumuk V., Tsigos C., Fried M., е. а. Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults // Obes Facts. 2015; 8 (6): 402-24. doi: 10.1159/000442721. Epub 2015 Dec 5.

46. Zheng Z., Peng F., Xu B., е. а. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis // J Infect. 2020 Aug; 81 (2): e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.

47. Zhou W., Shi Y., Li Y. Q., е. а. Body mass index, abdominal fatness, and hypertension incidence: a dose-response meta-analysis of prospective studies // J Hum Hypertens. 2018 May; 32 (5): 321-333. doi: 10.1038/s41371-018-0046-1. Epub 2018 Mar 27.

Valeology: Health - Illnes - recovery. 2021; : 5-12

ON THE ISSUE OF HYPERTENSION AGAINST THE BACKGROUND OF OBESITY DURING THE PANDEMIC OF CORONAVIRUS INFECTION COVID-19

BAIDURIN S. A., AKHMETZHANOVA SH. K.

Abstract

The review article details the data from the literature on the impact of hypertension and abdominal obesity on the course of coronavirus infection COVID-19. All over the world today, the prevalence of arterial hypertension (H) among the adult population is 30-45 %, and in people over 60 years old - more than 60%, which is caused not only by the aging of the population, but also by such behavioral risk factors as overweight and obesity. It is known that hypertension is twice as likely for people with abdominal obesity. A particular danger for patients with hypertension and overweight is the coronavirus infection COVID-19, especially in cases of severe course, which contributes to the occurrence of vascular thrombosis and decompensation of existing chronic diseases. In this regard, the review of the literature emphasizes the need to study the clinical and functional characteristics of hypertension in persons with abdominal obesity who have undergone coronavirus infection.

References

2. Arroyo-Johnson C., Mincey K. D. Obesity Epidemiology Worldwide. //Gastroenterol Clin. North. Am. 2016. - Dec; 45 (4): 571-579. doi: 10.1016/j.gtc.2016.07.012.

6. Boitsov S. A. Arterial'naya gipertoniya sredi lits 25-64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniya esse / S. A. Boitsov [i dr.] // KVTiP. – 2014. – № 4. – C. 4-14.

7. VOZ. Ozhirenie i izbytochnyi ves. – Aprel' 2020 //Informatsionnyi byulleten'.

9. Dzhidzhikhiya K. M. LEPTIN I ARTERIAL''NAYa GIPERTENZIYa PRI METABOLIChESKOM SINDROME K. M. Dzhidzhikhiya [i dr.] // Uspekhi sovremennogo estestvoznaniya. – 2013. – № 7. – S. 159-159A.

10. Ettehad, D., Emdin C. A., Kiran A., e. a. (2016) Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis // Lancet, 387, 957-967.

11. Erina A. M. Epidemiologiya arterial'noi gipertenzii v Rossiiskoi Federatsii – vazhnost' vybora kriteriev diagnostiki / A. M. Erina [i dr.] // Kardiologiya. – 2019. T. 59 (6). – S. 5-11.

12. Finer N., Garnett S. P., Bruun J. M. COVID-19 and obesity. // Clin Obes. 2020 Jun; 10 (3): e12365. doi: 10.1111/cob.12365. Epub 2020 Apr 27.

13. Földi M., Farkas N., Kiss S., e. a. KETLAK Study Group. Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis // Obes Rev. 2020 Oct; 21 (10): e13095. doi:10.1111/obr.13095. Epub 2020 Jul 19.

14. Garg S., Kim L., Whitaker M., e. a. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020 // MMWR Morb Mortal Wkly Rep. 2020 Apr 17; 69 (15): 458-464. doi: 10.15585/mmwr.mm6915e3.

15. Global B. M. I. Mortality Collaboration, Di Angelantonio E., Bhupathiraju Sh. N., Wormser D., e. a. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents // Lancet. 2016 Aug 20; 388 (10046): 776-86. doi: 10.1016/S0140-6736(16)30175-1. Epub 2016 Jul 13.

17. Ibragimova Kh. I. Polovye osobennosti regulyatsii arterial'nogo davleniya i lecheniya arterial'noi gipertenzii / Kh. I. Ibragimova, S. N. Mammaev, D. A. Omarova // Arterial'naya Gipertenziya. – 2018. – № 3. – S. 303-308.

20. Kim J. S., Lee J. Y., Yang J. W., e. a. Immunopathogenesis and treatment of cytokine storm in COVID-19 // Theranostics. 2021 Jan 1; 11 (1): 316-329. doi: 10.7150/thno.49713.

21. Konukoglu D., Uzun H. Endothelial Dysfunction and Hypertension // Adv Exp Med Biol. 2017; 956: 511-540. doi: 10.1007/5584_2016_90.

22. Kotsis V., Jordan J., Micic D., e. a. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment // J Hypertens. 2018 Jul; 36 (7): 1427-1440. doi: 10.1097/HJH.0000000000001730.

24. Luo D., Cheng Y., Zhang H., e. a. Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis // BMJ. 2020 Sep 9; 370: m3222. doi: 10.1136/bmj.m3222.

26. Mills K. T., Stefanescu A., He J. The global epidemiology of hypertension // Nat Rev Nephrol. 2020 Apr; 16 (4): 223-237. doi: 10.1038/s41581-019-0244-2. Epub 2020 Feb 5.

27. Muscogiuri G., Pugliese G., Barrea L., e. a. Commentary: Obesity: The "Achilles heel" for COVID-19? // Metabolism. 2020 Jul; 108: 154251. doi: 10.1016/j.metabol.2020.154251. Epub 2020 Apr 27.

28. Ononamadu C. J., Ezekwesili C. N., Onyeukwu O. F., e. a. Comparative analysis of anthropometric indices of obesity as correlates and potential predictors of risk for hypertension and prehypertension in a population in Nigeria // Cardiovasc J Afr. 2017 Mar / Apr 23; 28 (2): 92-99. doi: 10.5830/CVJA-2016-061. Epub 2016 Jul 13.

29. Osipova A. A. Rol' leptina v regulyatsii energeticheskogo obmena i funktsionirovanii organizmov zhivoi prirody / A. A. Osipova //Okruzhayushchaya sreda i energovedenie. – 2019. – № 2. – S. 55-82.

30. Pedralli M. L., Marschner R. A., Kollet D. P., e. a. Different exercise training modalities produce similar endothelial function improvements in individuals with prehypertension or hypertension: a randomized clinical trial Exercise, endothelium and blood pressure. //Sci Rep. 2020 May 6; 10 (1): 7628. doi: 10.1038/s41598-020-64365-x.

31. Pellicori P., Doolub G., Wong C. M., e. a. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies // Cochrane Database Syst Rev. 2021 Mar 11; 3 (3): CD013879. doi: 10.1002/14651858.CD013879.

34. Rahman M. M., Gilmour S. Prevention and control of hypertension in different countries // JAMA. 2014 Jan 22-29; 311 (4): 418-9. doi: 10.1001/jama.2013.285324.

35. Rapsomaniki E., Timmis A., George J., e. a. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people // Lancet. 2014 May 31; 383 (9932): 1899-911. doi: 10.1016/S0140-6736(14)60685-1.

37. Schmidt B. M., Durao S., Toews I., e. a. Screening strategies for hypertension // Cochrane Database Syst Rev. 2020 May 7; 5 (5): CD013212. doi: 10.1002/14651858.CD013212.pub2.

38. Scioli M. G., Storti G., D'Amico F., e. a. Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets // J Clin Med. 2020 Jun 25; 9 (6): 1995. doi: 10.3390/jcm9061995.

39. Shalnova S. A., Conradi A. O., Karpov Yu. A., e. a. Cardiovascular mortality in 12 Russian federation regions – participants of the “Cardiovascular disease epidemiology in Russian regions” study // Russ J Cardiol 2012; 5 (97): 6–11. Russian (Shal'nova S. A. Analiz smertnosti ot serdechno-sosudistykh zabolevanii v 12 regionakh Rossiiskoi Federatsii, uchastvuyushchikh v issledovanii “Epidemiologiya serdechno-sosudistykh zabolevanii v razlichnykh regionakh Rossii” S. A. Shal'nova [i dr.] // Rossiiskii kardiologicheskii zhurnal. – 2012. – 5 (97): 6–11).

40. Simonnet A., Chetboun M., Poissy J., e. a. LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation // Obesity (Silver Spring). 2020 Jul; 28 (7): 1195-1199. doi:10.1002/oby.22831. Epub 2020 Jun 10.

41. Vecchié A., Dallegri F., Carbone F., e. a. Obesity phenotypes and their paradoxical association with cardiovascular diseases. // Eur J Intern Med. 2018 Feb; 48: 6-17. doi: 10.1016/j.ejim.2017.10.020.

42. Williams B., Mancia G., Spiering W., e. a. ESC Scientific Document Group. 2018 ESC / ESH Guidelines for the management of arterial hypertension // Eur Heart J. 2018 Sep 1; 39 (33): 3021-3104. doi: 10.1093/eurheartj/ehy339.

45. Yumuk V., Tsigos C., Fried M., e. a. Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults // Obes Facts. 2015; 8 (6): 402-24. doi: 10.1159/000442721. Epub 2015 Dec 5.

46. Zheng Z., Peng F., Xu B., e. a. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis // J Infect. 2020 Aug; 81 (2): e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.

47. Zhou W., Shi Y., Li Y. Q., e. a. Body mass index, abdominal fatness, and hypertension incidence: a dose-response meta-analysis of prospective studies // J Hum Hypertens. 2018 May; 32 (5): 321-333. doi: 10.1038/s41371-018-0046-1. Epub 2018 Mar 27.